<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The activated leukocyte cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule (ALCAM, CD166) has been reported to be involved in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and to function as a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell marker </plain></SENT>
<SENT sid="1" pm="."><plain>Controversial data exist regarding the prognostic power of ALCAM expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we evaluate the expression of ALCAM in a cohort of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients and its usage as a prognostic marker for survival </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: Tissue specimens from 299 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> treated between 1993 and 2006 were analyzed via ALCAM immunohistochemistry (clone MOG/07) using a tissue microarray </plain></SENT>
<SENT sid="4" pm="."><plain>Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier analysis, and log-rank test, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis also was performed (Cox regression) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: ALCAM is expressed in most primary (76%) and secondary (62%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> lesions (P = 0.014) </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemistry revealed an inverse association with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grading (P = 0.002) but not with any other clinical or histopathological data </plain></SENT>
<SENT sid="8" pm="."><plain>Kaplan-Meier survival analysis revealed a significant overall survival benefit in the group of ALCAM-positive patients (P = 0.019) </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate analysis showed that ALCAM is an independent positive prognostic marker for overall survival (P = 0.023) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: ALCAM expression is a positive prognostic marker for overall survival of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, and its detection might help to optimize the existing prognostic staging system </plain></SENT>
<SENT sid="11" pm="."><plain>Elevated expression in higher differentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> might indicate a potential role in the early steps of <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, and its loss might be associated with reduced cellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, resulting in a higher metastatic potential of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Further studies must be conducted investigating these hypotheses </plain></SENT>
</text></document>